Verition Fund Management
NAUT icon

Verition Fund Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Verition Fund Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,995
Closed -$59K – 2535
2022
Q3 		$59K Hold
27,995
– – ﹤0.01% 2681
2022
Q2 		$75K Buy
27,995
+2,995
+12% +$11.1K ﹤0.01% 2104
2022
Q1 		$109K Hold
25,000
– – ﹤0.01% 2422
2021
Q4 		$130K Buy
25,000
+10,000
+67% +$53.5K ﹤0.01% 2301
2021
Q3 		$92K Hold
15,000
– – ﹤0.01% 1720
2021
Q2 		$152K Sell
15,000
-36,037
-71% -$390K ﹤0.01% 1640
2021
Q1 		$703K Buy
51,037
+36,037
+240% +$499K 0.01% 717
2020
Q4 		$163K Hold
15,000
– – ﹤0.01% 984
2020
Q3 		$161K Buy
+15,000
New +$160K ﹤0.01% 960

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Verition Fund Management's NAUT Position: Q4 2022 in Review

Verition Fund Management sold out of Nautilus Biotechnolgy (NAUT) in Q4 2022, closing a stake of 27,995 shares — an estimated $59K sold.

Verition Fund Management first reported a position in NAUT in Q3 2020 and held it in 9 quarters. The position peaked at $703K in Q1 2021. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2022.

  • Verition Fund Management reported no remaining Nautilus Biotechnolgy position as of Q4 2022 after selling out during the quarter.
  • Verition Fund Management sold 27,995 Nautilus Biotechnolgy shares in Q4 2022, an estimated $59K.
  • Verition Fund Management first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 9 quarters.
  • Verition Fund Management's Nautilus Biotechnolgy position peaked at $703K in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.